Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer, Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/16/2019 |
Start Date: | March 6, 2015 |
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
This randomized phase II trial studies how well tamoxifen citrate works compared with
z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby
tissue or lymph nodes or other parts of the body and has estrogen receptors but not human
epidermal growth factor receptor 2 (HER2) receptors on the surface of its cells. Estrogen can
cause the growth of tumor cells. Hormone therapy using tamoxifen citrate or z-endoxifen
hydrochloride may fight breast cancer by lowering the amount of estrogen the body makes. It
is not yet known whether tamoxifen citrate or z-endoxifen hydrochloride is more effective in
treating patients with breast cancer.
z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby
tissue or lymph nodes or other parts of the body and has estrogen receptors but not human
epidermal growth factor receptor 2 (HER2) receptors on the surface of its cells. Estrogen can
cause the growth of tumor cells. Hormone therapy using tamoxifen citrate or z-endoxifen
hydrochloride may fight breast cancer by lowering the amount of estrogen the body makes. It
is not yet known whether tamoxifen citrate or z-endoxifen hydrochloride is more effective in
treating patients with breast cancer.
PRIMARY OBJECTIVES:
I. To assess whether progression-free survival with z-endoxifen hydrochloride (HCl) relative
to that with tamoxifen (tamoxifen citrate) is prolonged in postmenopausal women with local
advanced or metastatic estrogen receptor (ER) positive/Her2 negative breast cancer.
SECONDARY OBJECTIVES:
I. To assess the safety profile of each of these agents in this patient population.
II. To assess whether the tumor response rate (as determined using the Response Evaluation
Criteria in Solid Tumors [RECIST] criteria) among those randomized to z-endoxifen HCl differs
from that among those randomized to tamoxifen.
III. To estimate the median progression-free survival time for those who receive z-endoxifen
HCl after disease progression with tamoxifen.
TERTIARY OBJECTIVES:
I. To examine whether ER alpha alterations (defined as either ER activating mutations or ER
amplification) are associated with longer progression-free survival (PFS) or higher response
rates in the z-endoxifen HCl arm compared to the tamoxifen arm.
II. To determine changes in lipid profiles comparing tamoxifen and z-endoxifen HCl.
III. For each treatment, to evaluate changes in markers of bone formation and absorption
after 12 weeks (4 cycles) of treatment.
IV. For all patients and by treatment arm, to determine whether progression-free survival
differs with respect to the sensitive to endocrine therapy (SET) index.
V. To examine whether deoxyribonucleic acid (DNA) alterations as measured by Foundation
medicine in all coding exons of 287 cancer-related genes as well as 78 polymorphisms in 34
absorption, distribution, metabolism, and excretion (ADME)-related genes are associated with
longer PFS or higher response rates in the z-endoxifen HCl arm compared to the tamoxifen arm.
VI. To assess whether the molecular characteristics identified in the tumor biopsies are
detectable in the circulating tumor cells (CTCs) and/or cell-free DNA (cfDNA).
VII. For each treatment arm: to examine changes in ER expression on CTCs, changes in estrogen
receptor (ESR) mutations or amplification in CTCs or CfDNA and explore the impact of these
changes on PFS and response rates.
VIII. To further characterize pharmacokinetics, pharmacogenetics and metabolism of
z-endoxifen HCl and tamoxifen.
IX. To determine the impact of the concentrations of tamoxifen and its metabolites on PFS in
the tamoxifen arm.
X. To determine the impact of the concentrations of z-endoxifen HCl and its metabolites on
PFS in the endoxifen arm.
XI. To determine the impact of genetic variation in the enzymes responsible for tamoxifen and
z-endoxifen HCl metabolism.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive z-endoxifen hydrochloride orally (PO) on days 1-21. Courses repeat
every 21 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive tamoxifen citrate PO once daily (QD) on days 1-21. Courses repeat
every 21 days in the absence of disease progression or unacceptable toxicity. Patients with
disease progression and bone metastases may cross over to Arm I and receive z-endoxifen
hydrochloride starting no later than 28 days after documentation of disease progression.
After completion of study treatment, patients are followed up yearly for up to 5 years.
I. To assess whether progression-free survival with z-endoxifen hydrochloride (HCl) relative
to that with tamoxifen (tamoxifen citrate) is prolonged in postmenopausal women with local
advanced or metastatic estrogen receptor (ER) positive/Her2 negative breast cancer.
SECONDARY OBJECTIVES:
I. To assess the safety profile of each of these agents in this patient population.
II. To assess whether the tumor response rate (as determined using the Response Evaluation
Criteria in Solid Tumors [RECIST] criteria) among those randomized to z-endoxifen HCl differs
from that among those randomized to tamoxifen.
III. To estimate the median progression-free survival time for those who receive z-endoxifen
HCl after disease progression with tamoxifen.
TERTIARY OBJECTIVES:
I. To examine whether ER alpha alterations (defined as either ER activating mutations or ER
amplification) are associated with longer progression-free survival (PFS) or higher response
rates in the z-endoxifen HCl arm compared to the tamoxifen arm.
II. To determine changes in lipid profiles comparing tamoxifen and z-endoxifen HCl.
III. For each treatment, to evaluate changes in markers of bone formation and absorption
after 12 weeks (4 cycles) of treatment.
IV. For all patients and by treatment arm, to determine whether progression-free survival
differs with respect to the sensitive to endocrine therapy (SET) index.
V. To examine whether deoxyribonucleic acid (DNA) alterations as measured by Foundation
medicine in all coding exons of 287 cancer-related genes as well as 78 polymorphisms in 34
absorption, distribution, metabolism, and excretion (ADME)-related genes are associated with
longer PFS or higher response rates in the z-endoxifen HCl arm compared to the tamoxifen arm.
VI. To assess whether the molecular characteristics identified in the tumor biopsies are
detectable in the circulating tumor cells (CTCs) and/or cell-free DNA (cfDNA).
VII. For each treatment arm: to examine changes in ER expression on CTCs, changes in estrogen
receptor (ESR) mutations or amplification in CTCs or CfDNA and explore the impact of these
changes on PFS and response rates.
VIII. To further characterize pharmacokinetics, pharmacogenetics and metabolism of
z-endoxifen HCl and tamoxifen.
IX. To determine the impact of the concentrations of tamoxifen and its metabolites on PFS in
the tamoxifen arm.
X. To determine the impact of the concentrations of z-endoxifen HCl and its metabolites on
PFS in the endoxifen arm.
XI. To determine the impact of genetic variation in the enzymes responsible for tamoxifen and
z-endoxifen HCl metabolism.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive z-endoxifen hydrochloride orally (PO) on days 1-21. Courses repeat
every 21 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive tamoxifen citrate PO once daily (QD) on days 1-21. Courses repeat
every 21 days in the absence of disease progression or unacceptable toxicity. Patients with
disease progression and bone metastases may cross over to Arm I and receive z-endoxifen
hydrochloride starting no later than 28 days after documentation of disease progression.
After completion of study treatment, patients are followed up yearly for up to 5 years.
Inclusion Criteria:
- PRE-REGISTRATION ELIGIBILITY CRITERIA
- Women who agree to undergo a standard of care core biopsy of recurrent or metastatic
breast cancer to confirm the ER+ (>= 10% nuclear staining) and HER2 negative status
- Patient must have been previously treated with an aromatase inhibitor (either
letrozole, anastrozole or exemestane) either in the adjuvant or metastatic setting,
and have one of the following types of primary or secondary endocrine resistant
disease
- Primary clinical resistance is defined as one of the following:
- Recurrence within the first 2 years of adjuvant endocrine therapy while on
aromatase inhibitor therapy
- Progression within first 6 months of initiating first-line endocrine therapy
(either aromatase inhibitor or fulvestrant containing regimen) for the
treatment of metastatic breast cancer
- Secondary clinical resistance is defined as one of the following:
- Recurrence after year 2 while receiving adjuvant aromatase inhibitor
therapy, or within 12 months of completing adjuvant aromatase inhibitor
therapy
- Progression occurring 6 or more months after initiating the first endocrine
therapy for metastatic disease (either fulvestrant or aromatase inhibitor
containing regimen)
- Patients with a history of measurable disease as defined by RECIST criteria or bone
only disease are eligible; Note: those patients with non-measurable disease and bone
metastases are eligible
- No history of tumors involving spinal cord or heart
- No current evidence of visceral crisis or lymphangitic spread
- No known brain metastases
- Women must be postmenopausal
- Postmenopausal status is verified by:
- Prior bilateral surgical oophorectomy, or
- Age >= 60 years, or
- Age < 60 with no menses for > 1 year with follicle-stimulating hormone (FSH)
and estradiol levels within post menopausal range, according to
institutional standard
- Prior treatment
- No more than two prior chemotherapy regimens in the metastatic setting
- Prior treatment with an aromatase inhibitor (either anastrozole, letrozole or
exemestane), either in the adjuvant or metastatic setting is required
- Unlimited prior endocrine regimens in the metastatic setting, which may have
included an everolimus or cyclin dependent kinase (CDK) 4/6 inhibitor (such as
palbociclib, abemaciclib or ribociclib) containing regimen
- Prior tamoxifen treatment is allowed in the adjuvant setting, but patients must
not have experienced relapse within 1 year of stopping tamoxifen
- No prior treatment with tamoxifen in the metastatic setting
- No prior treatment with endoxifen
- Patients who have not fully recovered from acute, reversible effects of prior
therapy regardless of interval since last treatment are not eligible to
participate in this study
- EXCEPTION: neuropathies-if grade 2 neuropathies have been stable for at
least 3 months since completion of prior treatment patient is eligible
- Not receiving any medications or substances that are strong inhibitors of cytochrome
P450 family 2, subfamily D, polypeptide 6 (CYP2D6)
- Not receiving any other investigational agents
- No uncontrolled intercurrent illness including, but not limited to:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Uncontrolled symptomatic cardiac arrhythmia
- Uncontrolled hypertension (defined as blood pressure > 160/90)
- None of the following co-morbid conditions:
- Cataracts of grade 2 or greater as per Common Terminology Criteria for Adverse
Events (CTCAE) version 4.0
- Retinopathy of grade 2 or greater as per CTCAE version 4.0
- Note: patients that have cataracts that do not require surgery are eligible
- Note: serious adverse events will be reported on CTEP-Adverse Event
Reporting System (AERS) using CTCAE version (v)5.0
- Deep vein thrombosis/pulmonary embolism (DVT/PE) within the past 6 months
- Note: patients that are on anticoagulant therapy for maintenance are
eligible as long as the DVT and/or PE occurred > 6 months prior to
enrollment, and there is no evidence for active thrombosis (either DVT or
PE)
- No other active second malignancy other than non-melanoma skin cancers within 3 years
of pre-registration; a second malignancy is not considered active if all treatment for
that malignancy is completed and the patient has been disease-free for at least 3
years prior to pre-registration
- Eastern Cooperative Oncology Group (ECOG) performance status: 0-2
- Able to swallow oral formulation of the study agent
- Hemoglobin >= 9 g/dL
- Platelet count >= 75,000/mm^3
- Creatinine =< 1.5 x upper limits of normal (ULN)
- Total bilirubin =< 1.5 x upper limits of normal (ULN)
- Aspartate aminotransferase (AST) =< 2.5 x upper limits of normal (ULN); for patients
with liver metastasis: =< 5 x upper limits of normal (ULN)
- REGISTRATION ELIGIBILITY CRITERIA
- Patients with either measurable disease as defined by RECIST criteria or bone only
disease are eligible; Note: those patients with both non-measurable disease and bone
metastases are eligible
- Non-measurable bone only disease: Non-measurable bone only disease may include
any of the following: blastic bone lesions, lytic bone lesions without a
measurable soft-tissue component, or mixed lytic-blastic bone lesions without a
measurable soft-tissue component
- Lytic bone lesions, with an identifiable soft tissue component, evaluated by
computed tomography (CT) or magnetic resonance imaging (MRI), can be considered
as measurable lesions if the soft tissue component otherwise meets the definition
of measurability previously described
- No tumors involving spinal cord or heart
- No visceral crisis, lymphangitic spread or known brain metastases: visceral crisis is
not the mere presence of visceral metastases, but implies severe organ dysfunction as
assessed by symptoms and signs, laboratory studies, and rapid progression of disease
- Histologic confirmation, from the A011203 pre-registration biopsy, by
institutional/local pathologist of either locally advanced or metastatic breast cancer
that is estrogen receptor positive and HER2 negative; those patients with bone only
disease with either no tumor or insufficient tumor for ER/progesterone receptor (PR)
and HER2 staining after the bone biopsy are still eligible to participate in this
study
- Estrogen receptor positive disease is defined as > 10% nuclear staining
- HER2 negative disease as per 2013 American Society of Clinical Oncology (ASCO)/College
of American Pathologists (CAP) guidelines, one of the following must apply:
- 0 or 1+ by immunohistochemistry (IHC) and not amplified by in situ hybridization
(ISH)
- 0 or 1+ by IHC and ISH not done
- 2+ by IHC and not amplified by ISH or
- IHC not done and not amplified by ISH
- None of the following therapies are allowed prior to registration:
- Chemotherapy =< 2 weeks
- Immunotherapy =< 2 weeks
- Biologic therapy =< 2 weeks
- Hormonal therapy =< 2 weeks
- Monoclonal antibodies =< 2 weeks
- Radiation therapy =< 2 weeks
- Anti-Her-2 or other "targeted" (e.g. mammalian target of rapamycin [mTOR])
therapy =< 2 weeks
- NOTE : Any toxicities derived from these therapies must be =< grade 2 prior
to starting study therapy
We found this trial at
568
sites
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
![University of New Mexico Cancer Center](/wp-content/uploads/logos/university-of-new-mexico-cancer-center.jpg)
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
361 Old Belgrade Road
Augusta, Maine 04330
Augusta, Maine 04330
(207) 621-6100
![Harold Alfond Center for Cancer Care](/wp-content/uploads/logos/harold-alfond-center-for-cancer-care.png)
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
![Lehigh Valley Hospital - Muhlenberg](/wp-content/uploads/logos/lehigh-valley-hospital---muhlenberg.png)
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
![Hurley Medical Center](/wp-content/uploads/logos/hurley-medical-center.png)
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
![University of Mississippi Medical Center](/wp-content/uploads/logos/university-of-mississippi-medical-center.png)
Principal Investigator: Barbara S. Craft
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
![West Michigan Cancer Center](/wp-content/uploads/logos/west-michigan-cancer-center.png)
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
![Providence Portland Medical Center](/wp-content/uploads/logos/providence-portland-medical-center.png)
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
808 North 39th Avenue
Yakima, Washington 98902
Yakima, Washington 98902
Principal Investigator: Keith S. Lanier
Phone: 503-215-6412
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1200 Old York Road
Abington, Pennsylvania 19001
Abington, Pennsylvania 19001
(215) 481–2000
![Abington Memorial Hospital](/wp-content/uploads/logos/abington-memorial-hospital.jpg)
Principal Investigator: Willard G. Andrews
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Allentown, Pennsylvania 18103
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anacortes, Washington 98221
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anaheim, California 92806
Principal Investigator: Gary L. Buchschacher
Phone: 626-564-3455
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99504
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
![Saint Joseph Mercy Hospital](/wp-content/uploads/logos/saint-joseph-mercy-hospital.jpg)
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Athens, Georgia 30607
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-1663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
Atlanta, Georgia 30342
(404) 851-8000
![Northside Hospital](/wp-content/uploads/logos/northside-hospital.jpg)
Principal Investigator: Amelia B. Zelnak
Phone: 404-303-3355
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Auburn, California 95602
Principal Investigator: Eunpi Cho
Phone: 415-209-2686
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Auburn, California 95603
Principal Investigator: Eunpi Cho
Phone: 415-209-2686
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 253-403-2394
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-1663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
![Rush - Copley Medical Center](/wp-content/uploads/logos/rush---copley-medical-center.png)
Principal Investigator: Maria T. Grosse-Perdekamp
Phone: 800-446-5532
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bakersfield, California 93301
Principal Investigator: Helen K. Chew
Phone: 916-734-3089
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baldwin Park, California 91706
Principal Investigator: Gary L. Buchschacher
Phone: 626-564-3455
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 800-821-7532
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
![Eastern Maine Medical Center](/wp-content/uploads/logos/eastern-maine-medical-center.png)
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70809
Principal Investigator: John T. Cole
Phone: 888-562-4763
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
![Bronson Battle Creek](/wp-content/uploads/logos/bronson-battle-creek.png)
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bellevue, Washington 98004
Principal Investigator: John A. Keech
Phone: 253-403-2394
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bellevue, Washington 98005
Principal Investigator: Keith S. Lanier
Phone: 503-215-6412
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bellflower, California 90706
Principal Investigator: Gary L. Buchschacher
Phone: 626-564-3455
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
![Strecker Cancer Center-Belpre](/wp-content/uploads/logos/strecker-cancer-center-belpre.jpg)
Principal Investigator: Timothy D. Moore
Phone: 614-488-2745
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Berkeley, California 94704
Principal Investigator: Eunpi Cho
Phone: 415-209-2686
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
![Saint Vincent Healthcare](/wp-content/uploads/logos/saint-vincent-healthcare.png)
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
![Sanford Bismarck Medical Center](/wp-content/uploads/logos/sanford-bismarck-medical-center.jpg)
Principal Investigator: Preston D. Steen
Phone: 701-234-6161
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
![Illinois CancerCare-Bloomington](/wp-content/uploads/logos/illinois-cancercare-bloomington.gif)
Principal Investigator: James L. Wade
Phone: 217-876-4740
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
![Saint Luke's Mountain States Tumor Institute](/wp-content/uploads/logos/saint-luke-s-mountain-states-tumor-institute.gif)
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Boise, Idaho 83706
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bonne Terre, Missouri 63628
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
![Bozeman Deaconess Hospital](/wp-content/uploads/logos/bozeman-deaconess-hospital.jpg)
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
Phone: 888-203-7267
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Brooklyn, New York 11203
Principal Investigator: Iuliana Shapira
Phone: 718-613-8324
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bryan, Texas 77802
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Burbank, California
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Burien, Washington 98166
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
![Saint James Community Hospital and Cancer Treatment Center](/wp-content/uploads/logos/saint-james-community-hospital-and-cancer-treatment-center.png)
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
3123 Medical Dr
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cameron Park, California 95682
Principal Investigator: Eunpi Cho
Phone: 415-209-2686
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
![Illinois CancerCare - Canton](/wp-content/uploads/logos/illinois-cancercare---canton.jpg)
Principal Investigator: James L. Wade
Phone: 217-876-4740
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2600 Sixth St. SW
Canton, Ohio 44710
Canton, Ohio 44710
330.363.4908
![Aultman Health Foundation](/wp-content/uploads/logos/aultman-health-foundation.gif)
Principal Investigator: Shruti Trehan
Phone: 330-363-6891
Aultman Health Foundation The Aultman Foundation will raise and administer funds in order to support...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
![Saint Francis Medical Center](/wp-content/uploads/logos/saint-francis-medical-center.png)
Principal Investigator: James L. Wade
Phone: 217-876-4740
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
(573) 519-4725
![Southeast Cancer Center](/wp-content/uploads/logos/southeast-cancer-center.png)
Principal Investigator: James L. Wade
Phone: 217-876-4740
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Carbondale, Illinois 62902
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
401 North Hooper Street
Caro, Michigan 48723
Caro, Michigan 48723
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Carterville, Illinois 62918
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
160 S Adams St
Carthage, Illinois 62321
Carthage, Illinois 62321
(217) 357-6877
![Illinois CancerCare - Carthage](/wp-content/uploads/logos/illinois-cancercare---carthage.jpg)
Principal Investigator: James L. Wade
Phone: 217-876-4740
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cary, North Carolina 27511
Principal Investigator: Mark L. Graham
Phone: 919-233-8585
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Castro Valley, California 94546
Principal Investigator: Eunpi Cho
Phone: 415-209-2686
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Centralia, Illinois 62801
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)